02:16 , Apr 22, 2017 |  BioCentury  |  Finance

Sweden heating up

Following a nearly 15-year deep freeze, Stockholm has become one of the hottest European markets for biotech IPOs. The recent boom reflects a ripening of several years of investment in the early stage life sciences...
23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
20:03 , Apr 7, 2017 |  BC Week In Review  |  Financial News

Biovica completes IPO

On March 28, diagnostic company Biovica International AB (SSE:BIOVIC B) raised SEK60 million ($6.7 million) through the sale of 4.8 million class B common shares at SEK12.50 in an IPO. Biovica International AB (SSE:BIOVIC B),...
23:54 , Feb 24, 2017 |  BC Extra  |  Company News

Management Tracks

Celgene Corp. (NASDAQ:CELG) said President and COO Jacqualyn Fouse will retire on June 30. Scott Smith will succeed Fouse effective April 1. He is president of global inflammation and immunology. Terrie Curran will be promoted...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Financial News

Biovica completes venture financing

Biovica International AB , Uppsala, Sweden   Business: Diagnostic   Date completed: 2016-06-20   Type: Venture financing   Raised: SEK30 million ($3.6 million)  ...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

cSens, Biovica deal

Biovica acquired fellow diagnostic company cSens in a “non-cash issue.” cSens’ PCR-based platform analyzes serum thymidine kinase enzyme activity to measure tumor and cancer progression. cSens did not respond to inquiries. cSens AB , Uppsala,...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Company News

Biovica, Karolinska Institute deal

The companies partnered to evaluate the efficacy of two 7,8-dihydro-8-oxoguanine triphosphatase ( NUDT1 ; MTH1) inhibitor cancer therapies from the institute using Biovica’s DiviTum assay. DiviTum measures cell proliferation rates. The institute declined to disclose...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Company News

Biovica, SimplicityBio deal

The companies partnered non-exclusively to combine Biovica’s DiviTum assay with SimplicityBio’s Biomarker Optimization Software System (BOSS) to discover, develop and commercialize improved multi-biomarker panels worldwide for advanced solid tumors. DiviTum measures cell proliferation rates for...